Details of the Drug
General Information of Drug (ID: DMA8LM5)
Drug Name |
Cyclopentolate
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Ciclopentolato; Cyclopentoiate; Cyclopentolatum; Cyclopentylate; Cylate; Diopentolate; Mydrilate; Bell Pentolate; Minims Cyclopentolate; Bell Pentolate (TN); Ciclopentolato [INN-Spanish]; Cyclopentolate (INN); Cyclopentolate [INN:BAN]; Cyclopentolatum [INN-Latin]; Ocu-Pentolate; B-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; Beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; Alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; (+-)-cyclopentolate; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester
|
||||||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||||||
Therapeutic Class |
Parasympatholytics
|
||||||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||||||
Structure | |||||||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 291.4 | |||||||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.7 | ||||||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 7 | ||||||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||||||
ADMET Property | |||||||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||||||
Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Disease Different from Cyclopentolate (Comorbidity)
|
References